Edit

Kriya Therapeutics

http://www.kriyatx.com/
Last activity: 29.06.2026
Active - Reference to Kriya Therapeutics
Categories: DesignIndustryInformationLifeManufacturingMarketPlatformProductionResearchTechnology
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed and manufactured – improving speed to market and delivering significant reductions in the cost per dose. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™). The company is advancing a deep and diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic and oncologic diseases. With locations in Silicon Valley, Calif., and Research Triangle Park, N.C., Kriya was founded by pioneers in the biopharmaceutical industry and is backed by blue-chip life sciences and technology investors. For more information, please visit www.kriyatx.com
Followers
4.84K
Mentions
2
Location: United States, California, Redwood City
Employees: 51-200
Total raised: $100M
Founded date: 2019

Funding Rounds 1

DateSeriesAmountInvestors
14.07.2021Series B$100MPatient Sq...

Mentions in press and media 2

DateTitleDescription
29.06.2026Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilitiesEli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot program, CNBC has learned. The FDA PreCheck program is designed t...
12.05.2020Kriya Therapeutics Raises $80M in Series A FinancingKriya Therapeutics, a Palo Alto, Calif. and Durham, N.C.-based gene therapy company, raised $80.5m in Series A financing. Investors included QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures (associated with Sutter Hill Ventures), Nar...

Reviews 0

Sign up to leave a review

Sign up Log In